SEC Form 4 · accession 0000939767-18-000174

EXELIXIS, INC. · EXEL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Pres Prod Dev & Med Aff & CMO

Period of report

Aug 1, 2018

Accepted (ET)

Aug 3, 2018 · 7:13 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000939767

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Aug 1, 2018	M	22,500	$5.50	A	300,788	D
Common Stock^F3	Aug 1, 2018	S	22,500	$20.56	D	278,288	D
Common Stock^F4	holding	—	—		—	14,505	I	By 401(k)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option (right to buy)^F5	$5.50	Aug 1, 2018	M	22,500	D	Sep 28, 2012	Sep 27, 2018	Common Stock	22,500	22,500	D

F1Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018.
F3Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.42 to $20.78. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of August 1, 2018.
F5The option, representing the right to purchase a total of 112,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 28, 2015.